Type 1 Cardiorenal Syndrome
Conditions
Interventions
Conventional diuretic group:Furosemide injection
Diuretic combined with rhBNP group:Furosemide injection+rh-BNP
Sponsors
Department of Critical Care Medicine, Tianjin First Center Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age >= 18 years; 2. Type 1 CRS (ultrasound indicating renal congestion or KDIGO AKI criteria); 3. MAP >= 65 mmHg; 4. Signs of congestion (edema, ascites, renal congestion, jugular vein distension, or pulmonary congestion); 5. NT-pro BNP: 450 ng/L; 50–75 years old >900 ng/L; >=75 years old >1800 ng/L; 6.After thorough communication, the patient agrees to participate in the study and signs the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Cardiogenic shock; 2. History of heart transplantation and/or ventricular assist device use; 3. Systolic blood pressure < 90 mmHg; 4. Baseline estimated glomerular filtration rate (eGFR) < 15 mL/min/1.73 m²; 5. Post-kidney transplantation; 6. Use of renal replacement therapy or ultrafiltration at any time prior to enrollment; 7. Expected exposure to nephrotoxic drugs (i.e., contrast agents) within 3 days; 8. Urinary tract obstruction; 9. End-stage malignant tumors; 10.Pregnant or breastfeeding women and patients with mental illness; 11. Patients who have difficulty participating in the study or undergoing follow-up, such as those who are non-compliant or have limited legal capacity; 12. Concurrent participation in other studies: Concurrent participation in other studies that may affect the results of this study or pose potential risks; 13.Allergy to the drugs involved in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Left Ventricular Ejection Fraction;VExUS score;Improvement rate in renal function after 1 week of treatment;Renal congestion (based on ultrasound evaluation); | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement rate of dyspnea before treatment, 1 day after treatment, 3 days after treatment, 5 days after treatment, and 7 days after treatment;30-day readmission rate;Ratio of invasive mechanical ventilation within 30 days;Renal replacement therapy rate within 30 days;Number of days receiving intravenous diuretic therapy;Mitral Annular Plane Systolic Excursion;Left ventricular cardiac function index;Diameter of the inferior vena cava; | — |
Countries
China
Contacts
Public ContactHongmei Gao
Department of Critical Care Medicine, Tianjin First Center Hospital
Outcome results
None listed